| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Products Intro: |
Product Name:BMS-502
CAS:2407854-18-4
Remarks:Reach out to us for more information about custom solutions.
|
BMS-502 manufacturers
- BMS-502
-
- $126.00 / 1mg
-
2025-11-09
- CAS:2407854-18-4
- Min. Order:
- Purity: 99.78%
- Supply Ability: 10g
- BMS-502
-
- $0.00 / 100MG
-
2025-03-16
- CAS:2407854-18-4
- Min. Order: 1MG
- Purity: 98
- Supply Ability: 100G
|
| | BMS-502 Basic information |
| Product Name: | BMS-502 | | Synonyms: | BMS-502;BMS-502 (Compound 22);BMS-502（SCHEMBL21830991）;8-(4-(Bis(4-fluorophenyl)methyl)piperazin-1-yl)-5-methyl-7-nitro-6-oxo-5,6-dihydro-1,5-naphthyridine-2-carbonitrile | | CAS: | 2407854-18-4 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | BMS-502 (COMPOU | | Mol File: | 2407854-18-4.mol |  |
| | BMS-502 Chemical Properties |
| solubility | DMF: 10 mg/ml
DMSO: 1 mg/ml | | form | Solid | | color | Light yellow to yellow |
| | BMS-502 Usage And Synthesis |
| Uses | BMS-502 (Compound 22) is a potent dual inhibitor of diacylglycerol kinase (DGK) α and ζ with IC50 of 4.6 nM and 2.1 nM. BMS-502 enhanced T cell immune responses in mice. BMS-502 can be used in tumor immunity related research[1]. | | Definition |
BMS-502 is a dual DGKα and ζ inhibitor. BMS-502 demonstrated dose-dependent immune stimulation in the mouse OT-1 model, setting the stage for a drug discovery program. BMS-502 demonstrated substantial inhibitory activity against DGKs α, ζ and ι[1].
| | in vivo | BMS-502 (Compound 22) (0-10mg/kg; PO; 24h) demonstrates dose-dependent immune stimulation in the mouse OT-1 model[1].
Pharmacokinetic Analysis in C57 black mice Model[1]
| Route | Dose (mg/kg) | AUClast (μM?h) | t1/2 (h) | Tmax (h) | Cmax (μM) | Cl (m/min/kg) | Vss (mL/kg) | F (%) | | i.v. | 1 | 14.8 | 22.5 | / | / | 1.9 | 3.9 | / | | p.o. | 5 | 48 | / | 3.0 | 1.08 | / | / | 65 |
| Animal Model: | OT-1 mouse model[1] | | Dosage: | 0-10 mg/kg | | Administration: | Oral administration; 24 h | | Result: | Caused no significant increase in activated effector T-cells. |
| | References | [1] Louis Chupak* and Susan Wee. “Discovery of Potent, Dual-Inhibitors of Diacylglycerol Kinases Alpha and Zeta Guided by Phenotypic Optimization.” ACS Medicinal Chemistry Letters 14 7 (2023): 929–935. |
| | BMS-502 Preparation Products And Raw materials |
|